Dr Thomas Michael Laton, DO | |
1980 Green St, Farrell, PA 16121-1355 | |
(724) 981-2253 | |
(724) 981-3218 |
Full Name | Dr Thomas Michael Laton |
---|---|
Gender | Male |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | 1980 Green St, Farrell, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053379446 | NPI | - | NPPES |
001208935006 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | OS005917L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Thomas Michael Laton, DO 2179 Parkdale Ave, Hermitage, PA 16148-2227 Ph: (724) 346-3601 | Dr Thomas Michael Laton, DO 1980 Green St, Farrell, PA 16121-1355 Ph: (724) 981-2253 |
News Archive
A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd. The study is thus fully recruited.
A new meta-analysis shows that pregnant women with endometriosis are at greater risk for a host of complications during pregnancy and at delivery, including preterm birth and cesarean section. The study was published in the journal Fertility and Sterility.
GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
An international team of researchers consisting of scientists from NUST MISIS and TU Dortmund University has developed a technology to study the behavior of orthopedic implants in laboratory conditions as close as possible to the human body.
› Verified 1 days ago